人类ABCG2：结构、功能及其在多药耐药中的作用。
Human ABCG2: structure, function, and its role in multidrug resistance.
作者信息
Mo Wei, Zhang Jian-Ting
机构信息
Department of Pharmacology and Toxicology and IU Simon Cancer Center, Indiana University School of Medicine Indianapolis, IN 46202, USA.
出版信息
Int J Biochem Mol Biol. 2012;3(1):1-27. Epub 2011 Mar 30.
Abstract
Human ABCG2 is a member of the ATP-binding cassette (ABC) transporter superfamily and is known to contribute to multidrug resistance (MDR) in cancer chemotherapy. Among ABC transporters that are known to cause MDR, ABCG2 is particularly interesting for its potential role in protecting cancer stem cells and its complex oligomeric structure. Recent studies have also revealed that the biogenesis of ABCG2 could be modulated by small molecule compounds. These modulators, upon binding to ABCG2, accelerate the endocytosis and trafficking to lysosome for degradation and effectively reduce the half-life of ABCG2. Hence, targeting ABCG2 stability could be a new venue for therapeutic discovery to sensitize drug resistant human cancers. In this report, we review recent progress on understanding the structure, function, biogenesis, as well as physiological and pathophysiological functions of ABCG2.
摘要
人类ABCG2是ATP结合盒（ABC）转运蛋白超家族的成员，已知其在癌症化疗中导致多药耐药（MDR）。在已知会导致MDR的ABC转运蛋白中，ABCG2因其在保护癌症干细胞中的潜在作用及其复杂的寡聚结构而特别引人关注。最近的研究还表明，小分子化合物可以调节ABCG2的生物合成。这些调节剂与ABCG2结合后，会加速内吞作用并转运至溶酶体进行降解，从而有效缩短ABCG2的半衰期。因此，靶向ABCG2的稳定性可能是治疗耐药性人类癌症的新治疗靶点。在本报告中，我们综述了关于ABCG2的结构、功能、生物合成以及生理和病理生理功能的最新研究进展。
相似文献
1
Human ABCG2: structure, function, and its role in multidrug resistance.人类ABCG2：结构、功能及其在多药耐药中的作用。
Int J Biochem Mol Biol. 2012;3(1):1-27. Epub 2011 Mar 30.
2
Reversal of ABCG2-mediated drug resistance by tinodasertib (ETC-206).替诺达西（ETC-206）逆转ABCG2介导的耐药性
Front Pharmacol. 2025 Jun 13;16:1606857. doi: 10.3389/fphar.2025.1606857. eCollection 2025.
3
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
5
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
6
Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters.鉴定作为ATP结合盒式药物外排转运蛋白底物的抗体药物偶联物有效载荷。
bioRxiv. 2025 May 27:2025.05.22.651305. doi: 10.1101/2025.05.22.651305.
8
Relationship Between Pituitary Gland and Stem Cell in the Aspect of Hormone Production and Disease Prevention: A Narrative Review.垂体与干细胞在激素产生和疾病预防方面的关系：一篇叙述性综述
Endocr Metab Immune Disord Drug Targets. 2025 Jan 13. doi: 10.2174/0118715303314551241031093717.
9
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.用于检测成人肺结核和利福平耐药性的Xpert® MTB/RIF检测
Cochrane Database Syst Rev. 2013 Jan 31(1):CD009593. doi: 10.1002/14651858.CD009593.pub2.
10
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理（2025年结石病专家共识）
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
引用本文的文献
1
Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌对PARPi耐药的机制
J Cell Mol Med. 2025 Aug;29(16):e70816. doi: 10.1111/jcmm.70816.
2
Neisseria meningitidis regulates P-glycoprotein transporter activity in brain endothelial cells via sphingosine 1-phosphate receptor 1.脑膜炎奈瑟菌通过鞘氨醇-1-磷酸受体1调节脑内皮细胞中的P-糖蛋白转运体活性。
Fluids Barriers CNS. 2025 Jul 22;22(1):78. doi: 10.1186/s12987-025-00687-0.
3
Elevated BCRP Transporter and Altered NF-кB Pathway Mediate Zoledronic Acid Resistance in MCF-7 Cells.BCRP转运蛋白升高和NF-кB信号通路改变介导MCF-7细胞对唑来膦酸的耐药性。
J Biochem Mol Toxicol. 2025 Jul;39(7):e70397. doi: 10.1002/jbt.70397.
4
Adipose-Derived Stem Cells at the Crossroads of Obesity and Cancer.处于肥胖与癌症交叉点的脂肪来源干细胞。
Stem Cell Rev Rep. 2025 Jul 3. doi: 10.1007/s12015-025-10918-4.
5
Outcomes Associated With ABCG2 and CD133 Expression in Patients With Gastric Cancer After Surgical Resection.胃癌手术切除患者中ABCG2和CD133表达相关的预后
Korean J Helicobacter Up Gastrointest Res. 2023 Dec;23(4):283-293. doi: 10.7704/kjhugr.2023.0039. Epub 2023 Dec 8.
6
Co-expression of HIF1A with multi-drug transporters (P-GP, MRP1, and BCRP) in chemoresistant breast, colorectal, and ovarian cancer cells.缺氧诱导因子1α（HIF1A）与多药转运蛋白（P-糖蛋白、多药耐药相关蛋白1和乳腺癌耐药蛋白）在耐化疗的乳腺癌、结直肠癌和卵巢癌细胞中的共表达。
J Genet Eng Biotechnol. 2025 Jun;23(2):100496. doi: 10.1016/j.jgeb.2025.100496. Epub 2025 May 1.
7
Inhibition of ABCG2 by SCO-101 Enhances Chemotherapy Efficacy in Cancer.SCO-101对ABCG2的抑制作用增强了癌症化疗疗效。
Int J Mol Sci. 2025 Apr 17;26(8):3790. doi: 10.3390/ijms26083790.
8
Reduction in Liver Cancer Risk by Quercetin via Modulation of Urate Levels: Insights from Drug-Target Mendelian Randomization.槲皮素通过调节尿酸水平降低肝癌风险：来自药物靶点孟德尔随机化的见解
Genes (Basel). 2025 Apr 13;16(4):449. doi: 10.3390/genes16040449.
9
PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer.PANTAX：一项Ib期临床试验，评估外排泵抑制剂SCO-101联合吉西他滨和纳米白蛋白结合型紫杉醇治疗不可切除或转移性胰腺癌的疗效。
Invest New Drugs. 2025 Apr;43(2):337-347. doi: 10.1007/s10637-025-01526-7. Epub 2025 Apr 24.
10
Mechanism of microRNA-152-3p-Mediated Regulation of Autophagy and Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells.微小RNA-152-3p介导的紫杉醇耐药卵巢癌细胞自噬及敏感性调控机制
Onco Targets Ther. 2025 Feb 4;18:179-197. doi: 10.2147/OTT.S485100. eCollection 2025.
本文引用的文献
1
Different roles of TM5, TM6, and ECL3 in the oligomerization and function of human ABCG2.TM5、TM6 和 ECL3 在人 ABCG2 寡聚化和功能中的不同作用。
Biochemistry. 2012 May 1;51(17):3634-41. doi: 10.1021/bi300301a. Epub 2012 Apr 19.
2
Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance.黄嘌呤类药物下调 ABCG2 药物转运体并逆转多药耐药。
Mol Pharmacol. 2012 Mar;81(3):328-37. doi: 10.1124/mol.111.075556. Epub 2011 Nov 23.
3
Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma.eIF3a 在调节顺铂敏感性和鼻咽癌核苷酸切除修复的翻译控制中的作用。
Oncogene. 2011 Dec 1;30(48):4814-23. doi: 10.1038/onc.2011.189. Epub 2011 May 30.
4
The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2.同源盒基因 MSX2 通过调节转运蛋白基因 ABCG2 决定胰腺癌细胞的化疗敏感性。
J Cell Physiol. 2012 Feb;227(2):729-38. doi: 10.1002/jcp.22781.
5
Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.人 P-糖蛋白（ABCB1）和乳腺癌耐药蛋白（ABCG2）对选定的 PET 放射性示踪剂的转运：体外筛选。
J Nucl Med. 2011 Mar;52(3):415-23. doi: 10.2967/jnumed.110.079608. Epub 2011 Feb 14.
6
Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.乳腺癌耐药蛋白 BCRP/ABCG2 调控 microRNAs（hsa-miR-328、-519c 和 -520h）及其在 ABCG2+肿瘤干细胞样细胞中的差异表达。
Biochem Pharmacol. 2011 Mar 15;81(6):783-92. doi: 10.1016/j.bcp.2010.12.018. Epub 2011 Jan 8.
7
Posttranslational negative regulation of glycosylated and non-glycosylated BCRP expression by Derlin-1.Derlin-1 对糖基化和非糖基化 BCRP 表达的翻译后负调控。
Biochem Biophys Res Commun. 2011 Jan 21;404(3):853-8. doi: 10.1016/j.bbrc.2010.12.074. Epub 2010 Dec 22.
8
Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.动态与静态 ABCG2 抑制剂增敏耐药癌细胞。
PLoS One. 2010 Dec 7;5(12):e15276. doi: 10.1371/journal.pone.0015276.
9
The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.生物类黄酮山奈酚是 Abcg2 的底物，并抑制 Abcg2 介导的槲皮素外排。
Drug Metab Dispos. 2011 Mar;39(3):426-32. doi: 10.1124/dmd.110.035212. Epub 2010 Dec 7.
10
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.乳腺癌耐药蛋白（ABCG2）在索拉非尼向脑部分布中的作用。
J Pharmacol Exp Ther. 2011 Jan;336(1):223-33. doi: 10.1124/jpet.110.175034. Epub 2010 Oct 15.
Zotero 插件